Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2008

View Archived Issues

BrainStorm reports results from rat study of NTF cells in Parkinson's disease

Novartis pays USD 25 million milestone payment to Antisoma in relation to ASA-404

4SC acquires stake in Nexigen and enters licensing agreement with ViroLogik

InSite signs Chinese licensing agreement with Essex Biotechnology for AzaSite

Human Genome Sciences presents an update on clinical development portfolio

Gene therapy for retinal albinism presented at the ASGT meeting

Murine von Willebrand disease ameliorated by helper-dependent adenovirus gene transfer

Boehringer Ingelheim gets first approval within E.U. for Actilyse

Antiinflammatory compound ND-07 improves experimental acute pancreatitis

Bristol-Myers Squibb to acquire cancer therapeutics company, Kosan Biosciences

FDA grants fast track to Wyeth's 13-valent pneumococcal conjugate vaccine

IntelGenx presents positive results from pilot pharmacokinetic study on CPI-300

Lipoxen reports phase I data for long-acting insulin candidate, SuliXen

SymBio completes enrollment in phase II study in indolent non-Hodgkin's lymphoma

Triphendiol safe in phase Ia pharmacokinetic study

Wyeth receives FDA approvable letter for Tygacil in community-acquired pneumonia

Phase I data show activity of NKTR-102 in solid tumor patients

Camurus reports positive phase II results for CAM-2028 in oral mucositis pain

Human Genome Sciences has initiated dosing in phase I HGS-1029

Novel antiinfective agents disclosed in recent GSK patents

Novel anti-HIV agents reported in recent patents

Nisshin Kyorin patent describes new therapeutic options for IBD

Genmab announces completion of pivotal phase III trial of ofatumumab in CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...